RMgmDB - Rodent Malaria genetically modified Parasites

Summary

RMgm-815
Malaria parasiteP. berghei
Genotype
DisruptedGene model (rodent): PBANKA_0833100; Gene model (P.falciparum): PF3D7_0932300; Gene product: M18 aspartyl aminopeptidase (M18AAP; DAP)
Transgene
Transgene not Plasmodium: A fusion of GFP (gfp-mu3) and Luciferase Firefly (LucIAV)
Promoter: Gene model: PBANKA_0915000; Gene model (P.falciparum): PF3D7_1133400; Gene product: apical membrane antigen 1 (ama-1)
3'UTR: Gene model: PBANKA_0719300; Gene product: bifunctional dihydrofolate reductase-thymidylate synthase, putative (dhfr/ts)
Replacement locus: Gene model: PBANKA_0306000; Gene product: 6-cysteine protein (230p)
PhenotypeNo phenotype has been described
Last modified: 23 December 2016, 17:44
  *RMgm-815
Successful modificationThe parasite was generated by the genetic modification
The mutant contains the following genetic modification(s) Gene disruption, Introduction of a transgene
Reference (PubMed-PMID number) Reference 1 (PMID number) : 25941254
MR4 number
Parent parasite used to introduce the genetic modification
Rodent Malaria ParasiteP. berghei
Parent strain/lineP. berghei ANKA
Name parent line/clone P. berghei ANKA 1037m1f1mocl1 (RMgm-32)
Other information parent lineP. berghei ANKA 1037m1f1mocl1 (1037cl1; RMgm-32) is a reference ANKA mutant line which expresses GFP-luciferase under control of a schizont-specific promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 20019192).
The mutant parasite was generated by
Name PI/ResearcherJ. Lin; C.J. Janse; S.M. Khan
Name Group/DepartmentLeiden Malaria Research Group
Name InstituteLeiden University Medical Center
CityLeiden
CountryThe Netherlands
Name of the mutant parasite
RMgm numberRMgm-815
Principal name2060cl1
Alternative name∆dap
Standardized name
Is the mutant parasite cloned after genetic modificationYes
Phenotype
Asexual blood stageNot different from wild type
Gametocyte/GameteNot tested
Fertilization and ookineteNot tested
OocystNot tested
SporozoiteNot tested
Liver stageNot tested
Additional remarks phenotype

Mutant/mutation
The mutant lacks expression of M18AAP (DAP)

Protein (function)
Plasmodium falciparum (PfM18AAP)is expressed by all intra-erythrocytic stages. Like the human aspartyl aminopeptidase, the metallo-exopeptidase activity of PfM18AAP is exclusive to N-terminal acidic amino acids, glutamate and aspartate.PfM18AAP is expressed in the cytosol.
 
Phenotype
Blood stages showed a normal growth/multiplication in mice (and produced normal levels of hemozoin).

Additional information
 

Figure: Generation of P. berghei mutants ∆app (RMgm-813), ∆lap (RMgm-814) and ∆dap (RMgm-815).
(primer sequences can either be found in Lin et al. (2015). J. Exp. Med. or obtained from the Leiden Malaria Research Group)
(A) Schematic representation of the gene-deletion constructs targeting the ORF of genes expressing aminopeptidase P (app), leucyl aminopeptidase (lap) and aspartyl aminopeptidase (dap) by double cross-over homologous recombination and the wt gene loci before and after disruption. The constructs contain a drug-selectable marker cassette (SM; black box) and gene target regions (hatched boxes). Primer positions (arrows) for diagnostic PCRs are shown (see Table S4 for primer sequences and expected product sizes). (B) Diagnostic PCR (left) and Southern analysis of pulsed field gel-separated chromosomes (center) confirm correct disruption of app in ∆app-a and ∆app-b. Northern analysis of blood-stage mRNA (right) confirms the absence of the app transcripts in the ∆app mutants. The following primers were used for diagnostic PCRs: 5' integration (5’ in): L7107/L4770; 3' integration (3’ in): L4771/L7108; SM (hdfhr::yfcuI): L4698/L4699; app ORF: L7109/L7110. Separated chromosomes of ∆app-a and ∆app-b were hybridized using a 3’UTR pbdhfr probe that recognizes the construct integrated into the app locus on chromosome 13, the endogenous dhfr/ts on chromosome 7 and the GFP-luciferase reporter cassette in the 230p locus on chromosome 3. Northern blot was hybridized using a PCR probe recognizing the app ORF (primers L7109/L7110) and with an oligonucleotide probe L644R recognizing the large subunit rRNA (as loading control). (C) Diagnostic PCR (left) and Southern analysis of separated chromosomes (center) confirm correct disruption of lap in mutant ∆lap. Northern analysis of blood-stage mRNA (right) confirms the absence of lap transcripts in the ∆lap mutant. The following primers were used for diagnostic PCRs: 5’ in, L6967/L4770; 3’ in, L4771/L6968; SM (hdfhr::yfcu), L4698/L4699; lap ORF, L6969/L6970. Separated chromosomes were hybridized using a 3’UTR pbdhfr probe that recognizes the construct integrated into lap on chromosome 13, the endogenous dhfr/ts on chromosome 7 and the GFP-luciferase reporter cassette in the 230p locus on chromosome 3. Northern blot was hybridized using a PCR probe recognizing lap ORF (primers L6969/L6970) and with an oligonucleotide probe L644R recognizing the large subunit rRNA (as loading control). (D) Diagnostic PCR (left) and Southern analysis of pulsed field gel-separated chromosomes (center) confirm correct disruption of dap in ∆dap. Northern analysis of blood-stage mRNA (right) confirms the absence of the lap transcripts in the ∆dap mutant. The following primers were used for diagnostic PCRs: 5’ in, L6975/L4770; 3’ in, L4771/L6976; SM (hdfhr::yfcu), L4698/L4699; dap ORF, L6977/L6978. Separated chromosomes were hybridized using a 3’UTR pbdhfr probe that recognizes the construct integrated into dap on chromosome 8, the endogenous dhfr/ts on chromosome 7 and the GFP-luciferase reporter cassette in the 230p locus on chromosome 3. For Northern blot was hybridized using a PCR probe recognizing dap ORF (primers L6977/L6978) and with an oligonucleotide probe L644R recognizing the large subunit rRNA (as loading control). See Table S4 for primers used for generation of probes.

Other mutants


  Disrupted: Mutant parasite with a disrupted gene
Details of the target gene
Gene Model of Rodent Parasite PBANKA_0833100
Gene Model P. falciparum ortholog PF3D7_0932300
Gene productM18 aspartyl aminopeptidase
Gene product: Alternative nameM18AAP; DAP
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct used(Linear) PCR construct double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Click to view information
Click to hide information
Plasmid/construct sequence
Click to view information
Click to hide information
GAACTCGTACTCCTTGGTGACGTCGCGATGTTGAAGGCATAATAAAACAGCAGCTATTGG
TTATTTATTATATGAAAAAAAATATATATAGTGCCGAAACTTTCTACAAAAATCGAACAG
AAAGAGGATTTATAAATATTAACAAAATAGGTGTAGTAATAAATTGTATCGATAGTATAT
ACACTTATTTATGAAGCAACGTAGAGTATTCATTCATTAAAACATTTAATATTCTATTCT
TTTTACAATCCATGGGCTTATTATAATGATTTGCCACATGTTTCATACCAATTAAAATAA
TTTAAAATGATTAAAGTAAATTTTATTTTATTTTATTTTATTTTAGTTATTTTTTTCTAT
TCTTAGTACACCAAACATATATACAGTATGTATGTACATTTTCGATAAGCCACTGATAAA
AAAATAAAAATATCGATTTTATTTACTCTTGTTTTTTTATGCATTATAATATATGCCTCA
AATTTTTATATTCTATTATTATTTTGTATATATATGCATATATAATATCCAAAGTATAGA
AAACAAAAATATTTGAATTATCAAAAATGATAAAAAAGCATATGACTGGAAATATGCCAT
TTCACTAAAATACAAACTAGTTTTATACATTTTTTTATATTTCCAACATATCTATAAAAA
AAATAATATTATAATTTTTTTTTTATTTTAATTTAATATGATAAAATAGCTAGCTTGTTA
ATGCGATTTGTATCATATGTTATAAGTATTTTTATTTTATAAAAATATTTGAAATATACA
CATACAAAATCCACAACATAGTGTAAGTGTAGGCATATCGTATGTATATGAGGTCGACGA
TGCTTGTAGATGGCCCAGCTTAATTCTTTTCGAGCTCTTTATGCTTAAGTTTACAATTTA
ATATTCATACTTTAAGTATTTTTTGTAGTATCCTAGATATTGTGCTTTAAATGCTCACCC
CTCAAAGCACCAGTAATATTTTCATCCACTGAAATACCATTAAATTTTCAAAAAAATACT
ATGCATATAATGTTATACATATAAACATAAAACGCCATGTAAATCAAAAAATATATAAAA
ATATGTATAAAAATAAATATGCACTAAATATAAGCTAATTATGCATAAAAATTAAAGTGC
CCTTTATTAACTAGTCGTAATTATTTATATTTCTATGTTATAAAAAAATCCTCATATAAT
AATATAATTAATATATGTAATGTTTTTTTTATTTTATAATTTTAATATAAAATAATATGT
AAATTAATTCAAAAAATAAATATAATTGTTGTGAAACAAAAAACGTAATTTTTTCATTTG
CCTTCAAAATTTAAATTTATTTTAATATTTCCTAAAATATATATACTTTGTGTATAAATA
TATAAAAATATATATTTGCTTATAAATAAATAAAAAATTTTATAAAACATAGGGGGATCC
ATGGTTGGTTCGCTAAACTGCATCGTCGCTGTGTCCCAGAACATGGGCATCGGCAAGAAC
GGGGACCTGCCCTGGCCACCGCTCAGGAACGAATTTAGATATTTCCAGAGAATGACCACA
ACCTCTTCAGTAGAAGGTAAACAGAATCTGGTGATTATGGGTAAGAAGACCTGGTTCTCC
ATTCCTGAGAAGAATCGACCTTTAAAGGGTAGAATTAATTTAGTTCTCAGCAGAGAACTC
AAGGAACCTCCACAAGGAGCTCATTTTCTTTCCAGAAGTCTAGATGATGCCTTAAAACTT
ACTGAACAACCAGAATTAGCAAATAAAGTAGACATGGTCTGGATAGTTGGTGGCAGTTCT
GTTTATAAGGAAGCCATGAATCACCCAGGCCATCTTAAACTATTTGTGACAAGGATCATG
CAAGACTTTGAAAGTGACACGTTTTTTCCAGAAATTGATTTGGAGAAATATAAACTTCTG
CCAGAATACCCAGGTGTTCTCTCTGATGTCCAGGAGGAGAAAGGCATTAAGTACAAATTT
GAAGTATATGAGAAGAATGATGCTAGCGGAGGAGGTGGATCTGGTGGAGGTGGAAGTGCT
AGCGTGACAGGGGGAATGGCAAGCAAGTGGGATCAGAAGGGTATGGACATTGCCTATGAG
GAGGCGGCCTTAGGTTACAAAGAGGGTGGTGTTCCTATTGGCGGATGTCTTATCAATAAC
AAAGACGGAAGTGTTCTCGGTCGTGGTCACAACATGAGATTTCAAAAGGGATCCGCCACA
CTACATGGTGAGATCTCCACTTTGGAAAACTGTGGGAGATTAGAGGGCAAAGTGTACAAA
GATACCACTTTGTATACGACGCTGTCTCCATGCGACATGTGTACAGGTGCCATCATCATG
TATGGTATTCCACGCTGTGTTGTCGGTGAGAACGTTAATTTCAAAAGTAAGGGCGAGAAA
TATTTACAAACTAGAGGTCACGAGGTTGTTGTTGTTGACGATGAGAGGTGTAAAAAGATC
ATGAAACAATTTATCGATGAAAGACCTCAGGATTGGTTTGAAGATATTGGTGAGGCTTCG
GAACCATTTAAGAACGTCTACTTGCTACCTCAAACAAACCAATTGCTGGGTTTGTACACC
ATCATCAGAAATAAGAATACAACTAGACCTGATTTCATTTTCTACTCCGATAGAATCATC
AGATTGTTGGTTGAAGAAGGTTTGAACCATCTACCTGTGCAAAAGCAAATTGTGGAAACT
GACACCAACGAAAACTTCGAAGGTGTCTCATTCATGGGTAAAATCTGTGGTGTTTCCATT
GTCAGAGCTGGTGAATCGATGGAGCAAGGATTAAGAGACTGTTGTAGGTCTGTGCGTATC
GGTAAAATTTTAATTCAAAGGGACGAGGAGACTGCTTTACCAAAGTTATTCTACGAAAAA
TTACCAGAGGATATATCTGAAAGGTATGTCTTCCTATTAGACCCAATGCTGGCCACCGGT
GGTAGTGCTATCATGGCTACAGAAGTCTTGATTAAGAGAGGTGTTAAGCCAGAGAGAATT
TACTTCTTAAACCTAATCTGTAGTAAGGAAGGGATTGAAAAATACCATGCCGCCTTCCCA
GAGGTCAGAATTGTTACTGGTGCCCTCGACAGAGGTCTAGATGAAAACAAGTATCTAGTT
CCAGGGTTGGGTGACTTTGGTGACAGATACTACTGTGTTTAACTCGATCCCGTTTTTCTT
ACTTATATATTTATACCAATTGATTGTATTTATAACTGTAAAAATGTGTATGTTGTGTGC
ATATTTTTTTTTGTGCATGCACATGCATGTAAATAGCTAAAATTATGAACATTTTATTTT
TTGTTCAGAAAAAAAAAACTTTACACACATAAAATGGCTAGTATGAATAGCCATATTTTA
TATAAATTAAATCCTATGAATTTATGACCATATTAAAAATTTAGATATTTATGGAACATA
ATATGTTTGAAACAATAAGACAAAATTATTATTATTATTATTATTTTTACTGTTATAATT
ATGTTGTCTCTTCAATGATTCATAAATAGTTGGACTTGATTTTTAAAATGTTTATAATAT
GATTAGCATAGTTAAATAAAAAAAGTTGAAAAATTAAAAAAAAACATATAAACACAAATG
ATGTTTTTTCCTTCAACCTTCAATTTCGGATCCACTAGCAGTCAAATTATAAGTACAAAG
GAAAATCCACACACATTGGCATTATATAGAAATTGAGAAAAAATTATACGCACACCCCCC
CAAAAAAATGTTTATGTACTAATTCAAGGAATCATATCACTACAATGAAATACTTGTGAT
ATAATAACATTATATTTCGTACATTTTTTAATATTCATTTAAATTTATCTCTAATATATA
AATGTCGGCATTTCCGCAATAAGCCACATTTTTTTTTACATATGATTTTATTATTTATAC
ATTTTCAACAAATCTGATAAATAAAAATGAGCAATATTCAGCACTTTTTGTGTCTTTTAA
TATATGATAAATAGAACTATAAACGAAAAAAATTAATTTTAAATATACTTTTTCATTTTT
CTTAAACAACGCAGATTAAGTTCCCTTTTATTTTATTCACTAAAAACGCTTTTAAAATTT
TGCACATGTGTATTATGTTTCATGCATAATTTTTATGGAATATCAACATTCTTCTTTTTT
AATAAAACCTTATTATACCATAATGAATAAAATGTATAAAAAAAAGCTTTATACTTATGC
AATATAAATTATATGTAAAAAAATAATGTGCATATGCGCATGCATATACATATGAATAAT
GTGACCAAAAAAACATGACATCCATAAAATTGGAAAGTGGCCATGGTATTGTTATATAAT
TGTCAATGTTTAATGCAATATTTTTCTAATTACAGATAGGGAAAATAAATAATACACACA
TATATATGCATACATCCATGCAATATGCATTTTAATGTCGCGAGCTGAGTGTCAATGACC
AACCT
Restriction sites to linearize plasmid
Partial or complete disruption of the geneComplete
Additional remarks partial/complete disruption
Selectable marker used to select the mutant parasitehdhfr/yfcu
Promoter of the selectable markereef1a
Selection (positive) procedurepyrimethamine
Selection (negative) procedureNo
Additional remarks genetic modificationThe locus was targeted using a linear construct that was generated using a 2-step, anchor tagging PCR method (for primer details see below).

The 5’- and 3’ targeting regions of the gene were PCR amplified from genomic DNA using primer pairs 1&2 and 3&4. Primers 2 and 3 have 5’-terminal extensions homologues to the hdhfr::yfcu selectable marker cassette. Primers 1 and 4 both have a 5’-terminal overhang with an anchor-tag which serves as a primer site in the 2nd PCR reaction.

The target fragments from the first PCR reaction were annealed to either side of the selectable marker cassette by PCR with anchor-tag primers 5 and 6, resulting in the 2nd PCR product. The hdhfr::yfcu selectable marker cassette used in this reaction was digested from pL0048 using restriction enzymes XhoI and NotI. pL0048 is available from The Leiden Malaria Research Group.

See for more information on the 2-step anchor tagging PCR method, the following publications:
J.W. Lin, S.M. Khan et al. A novel 'gene insertion/marker out' (GIMO) method for transgene expression and gene complementation in rodent malaria parasites PLoS One. 2011;6(12).
T. Annoura et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates Vaccine. 2012;30(16):2662-70
Additional remarks selection procedure
Primer information: Primers used for amplification of the target sequences  Click to view information
Primer information: Primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1L6971; dap 5’-targeting sequence, F (NruI)
Additional information primer 1GAACTCGTACTCCTTGGTGACGTCGCGATGTTGAAGGCATAATAAAACAG
Sequence Primer 2L6972; dap 5’-targeting sequence, R
Additional information primer 2CATCTACAAGCATCGTCGACCTCATATACATACGATATGCCTACAC
Sequence Primer 3L6973; dap 3’-targeting sequence, F
Additional information primer 3CCTTCAATTTCGGATCCACTAGCAGTCAAATTATAAGTACAAAGG
Sequence Primer 4L6974; dap 3’-targeting sequence, R (NruI)
Additional information primer 4AGGTTGGTCATTGACACTCAGCTCGCGACATTAAAATGCATATTGCATGG
Sequence Primer 5GAACTCGTACTCCTTGGTGACG
Additional information primer 5L4661; anchor tag primer
Sequence Primer 6AGGTTGGTCATTGACACTCAGC
Additional information primer 6L4662: anchor tag primer

  Transgene: Mutant parasite expressing a transgene
Type and details of transgene
Is the transgene Plasmodium derived Transgene: not Plasmodium
Transgene nameA fusion of GFP (gfp-mu3) and Luciferase Firefly (LucIAV)
Details of the genetic modification
Inducable system usedNo
Additional remarks inducable system
Type of plasmid/construct(Linear) plasmid double cross-over
PlasmoGEM (Sanger) construct/vector usedNo
Modified PlasmoGEM construct/vector usedNo
Plasmid/construct map
Plasmid/construct sequence
Restriction sites to linearize plasmid KspI (SacII)
Selectable marker used to select the mutant parasitegfp (FACS)
Promoter of the selectable markerama-1
Selection (positive) procedureFACS (flowsorting)
Selection (negative) procedureNo
Additional remarks genetic modificationThe GFP-Luciferase gene (1 copy) has been inserted into the 230p locus (PB000214.00.0) by double cross-over integration.
Additional remarks selection procedureThis reporter mutant expressing GFP-Luciferase does not contain a drug-selectable marker. This mutant has been selected by FACS sorting after transfection based on GFP fluorescence.
Other details transgene
Promoter
Gene Model of Parasite PBANKA_0915000
Gene Model P. falciparum ortholog PF3D7_1133400
Gene productapical membrane antigen 1
Gene product: Alternative nameama-1
Primer information details of the primers used for amplification of the promoter sequence  Click to view information
Primer information details of the primers used for amplification of the promoter sequence  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
3'-UTR
Gene Model of Parasite PBANKA_0719300
Gene productbifunctional dihydrofolate reductase-thymidylate synthase, putative
Gene product: Alternative namedhfr/ts
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to view information
Primer information details of the primers used for amplification the 3'-UTR sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Insertion/Replacement locus
Replacement / InsertionReplacement locus
Gene Model of Parasite PBANKA_0306000
Gene product6-cysteine protein
Gene product: Alternative name230p
Primer information details of the primers used for amplification of the target sequences  Click to view information
Primer information details of the primers used for amplification of the target sequences  Click to hide information
Sequence Primer 1
Additional information primer 1
Sequence Primer 2
Additional information primer 2
Sequence Primer 3
Additional information primer 3
Sequence Primer 4
Additional information primer 4